Annual CFF
$54.11 M
-$20.95 M-27.91%
31 December 2023
Summary:
Heron Therapeutics annual cash flow from financing activities is currently $54.11 million, with the most recent change of -$20.95 million (-27.91%) on 31 December 2023. During the last 3 years, it has risen by +$45.00 million (+494.26%). HRTX annual CFF is now -84.87% below its all-time high of $357.61 million, reached on 31 December 2018.HRTX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$14.00 K
-$478.00 K-97.15%
30 September 2024
Summary:
Heron Therapeutics quarterly cash flow from financing activities is currently $14.00 thousand, with the most recent change of -$478.00 thousand (-97.15%) on 30 September 2024. Over the past year, it has dropped by -$53.78 million (-99.97%). HRTX quarterly CFF is now -100.00% below its all-time high of $370.42 million, reached on 30 June 2018.HRTX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$716.00 K
-$53.78 M-98.69%
30 September 2024
Summary:
Heron Therapeutics TTM cash flow from financing activities is currently $716.00 thousand, with the most recent change of -$53.78 million (-98.69%) on 30 September 2024. Over the past year, it has dropped by -$53.63 million (-98.68%). HRTX TTM CFF is now -99.86% below its all-time high of $526.17 million, reached on 30 June 2018.HRTX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
HRTX Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -27.9% | -100.0% | -98.7% |
| 3 y3 years | +494.3% | +119.7% | -99.6% |
| 5 y5 years | -84.9% | -99.6% | -97.1% |
HRTX Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -65.3% | +494.3% | -100.0% | +102.2% | -99.6% | +661.7% |
| 5 y | 5 years | -84.9% | +494.3% | -100.0% | +102.2% | -99.6% | +661.7% |
| alltime | all time | -84.9% | +1863.6% | -100.0% | +100.1% | -99.9% | +103.0% |
Heron Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $14.00 K(-97.2%) | $716.00 K(-98.7%) |
| June 2024 | - | $492.00 K(+4372.7%) | $54.50 M(+0.3%) |
| Mar 2024 | - | $11.00 K(-94.5%) | $54.33 M(+0.4%) |
| Dec 2023 | $54.11 M(-27.9%) | $199.00 K(-99.6%) | $54.11 M(-0.4%) |
| Sept 2023 | - | $53.80 M(>+9900.0%) | $54.35 M(-28.0%) |
| June 2023 | - | $319.00 K(-253.4%) | $75.49 M(+0.0%) |
| Mar 2023 | - | -$208.00 K(-147.4%) | $75.49 M(+0.6%) |
| Dec 2022 | $75.06 M(-51.9%) | $439.00 K(-99.4%) | $75.06 M(-0.1%) |
| Sept 2022 | - | $74.94 M(>+9900.0%) | $75.11 M(>+9900.0%) |
| June 2022 | - | $315.00 K(-149.5%) | $94.00 K(-99.9%) |
| Mar 2022 | - | -$637.00 K(-230.8%) | $154.51 M(-1.0%) |
| Dec 2021 | $156.03 M(+1613.7%) | $487.00 K(-785.9%) | $156.03 M(-3.3%) |
| Sept 2021 | - | -$71.00 K(-100.0%) | $161.30 M(-0.4%) |
| June 2021 | - | $154.73 M(>+9900.0%) | $161.90 M(+1607.6%) |
| Mar 2021 | - | $883.00 K(-84.7%) | $9.48 M(+4.1%) |
| Dec 2020 | $9.11 M(-95.1%) | $5.76 M(+999.6%) | $9.11 M(-94.6%) |
| Sept 2020 | - | $524.00 K(-77.3%) | $168.47 M(-2.0%) |
| June 2020 | - | $2.31 M(+356.0%) | $171.86 M(-4.7%) |
| Mar 2020 | - | $507.00 K(-99.7%) | $180.39 M(-3.2%) |
| Dec 2019 | $186.43 M(-47.9%) | $165.13 M(+4118.9%) | $186.43 M(+665.3%) |
| Sept 2019 | - | $3.91 M(-63.9%) | $24.36 M(+4121.8%) |
| June 2019 | - | $10.85 M(+65.9%) | $577.00 K(-99.8%) |
| Mar 2019 | - | $6.54 M(+113.6%) | $360.15 M(+0.7%) |
| Dec 2018 | $357.61 M(+21.7%) | $3.06 M(-115.4%) | $357.61 M(-28.6%) |
| Sept 2018 | - | -$19.87 M(-105.4%) | $501.12 M(-4.8%) |
| June 2018 | - | $370.42 M(+9167.4%) | $526.17 M(+298.2%) |
| Mar 2018 | - | $4.00 M(-97.3%) | $132.13 M(-55.0%) |
| Dec 2017 | $293.73 M(+411.2%) | $146.57 M(+2730.7%) | $293.73 M(+97.6%) |
| Sept 2017 | - | $5.18 M(-121.9%) | $148.64 M(-23.5%) |
| June 2017 | - | -$23.62 M(-114.3%) | $194.43 M(-11.8%) |
| Mar 2017 | - | $165.60 M(>+9900.0%) | $220.52 M(+283.8%) |
| Dec 2016 | $57.45 M(-58.4%) | $1.48 M(-97.1%) | $57.45 M(-0.5%) |
| Sept 2016 | - | $50.97 M(+1958.4%) | $57.73 M(+589.9%) |
| June 2016 | - | $2.48 M(-2.1%) | $8.37 M(-93.9%) |
| Mar 2016 | - | $2.53 M(+43.8%) | $137.64 M(-0.3%) |
| Dec 2015 | $137.99 M(+122.2%) | $1.76 M(+9.7%) | $137.99 M(+1.0%) |
| Sept 2015 | - | $1.60 M(-98.8%) | $136.57 M(+0.8%) |
| June 2015 | - | $131.75 M(+4477.9%) | $135.49 M(+111.6%) |
| Mar 2015 | - | $2.88 M(+744.0%) | $64.03 M(+3.1%) |
| Dec 2014 | $62.11 M(+1.4%) | $341.00 K(-34.2%) | $62.11 M(-48.8%) |
| Sept 2014 | - | $518.00 K(-99.1%) | $121.25 M(-0.5%) |
| June 2014 | - | $60.29 M(+6193.4%) | $121.81 M(+97.8%) |
| Mar 2014 | - | $958.00 K(-98.4%) | $61.58 M(+0.6%) |
| Dec 2013 | $61.23 M(+14.4%) | $59.48 M(+5412.9%) | $61.23 M(+3390.8%) |
| Sept 2013 | - | $1.08 M(+1898.1%) | $1.75 M(-96.6%) |
| June 2013 | - | $54.00 K(-91.2%) | $51.17 M(-5.5%) |
| Mar 2013 | - | $612.00 K(+6700.0%) | $54.13 M(+1.1%) |
| Dec 2012 | $53.51 M(+122.1%) | $9000.00(-100.0%) | $53.51 M(+0.4%) |
| Sept 2012 | - | $50.49 M(+1575.8%) | $53.32 M(+905.7%) |
| June 2012 | - | $3.01 M(>+9900.0%) | $5.30 M(-78.0%) |
| Mar 2012 | - | $0.00(-100.0%) | $24.10 M(0.0%) |
| Dec 2011 | $24.10 M(>+9900.0%) | -$183.00 K(-107.4%) | $24.10 M(-0.8%) |
| Sept 2011 | - | $2.47 M(-88.7%) | $24.30 M(+11.3%) |
| June 2011 | - | $21.81 M(>+9900.0%) | $21.83 M(>+9900.0%) |
| Dec 2010 | $77.00 K(-99.0%) | $17.00 K(>+9900.0%) | $77.00 K(-99.0%) |
| Sept 2010 | - | $0.00(-100.0%) | $8.04 M(-0.1%) |
| June 2010 | - | $18.00 K(-57.1%) | $8.05 M(-0.1%) |
| Mar 2010 | - | $42.00 K(-99.5%) | $8.06 M(+0.6%) |
| Dec 2009 | $8.01 M(>+9900.0%) | $7.98 M(>+9900.0%) | $8.01 M(>+9900.0%) |
| Sept 2009 | - | $5000.00(-81.5%) | $54.00 K(+10.2%) |
| June 2009 | - | $27.00 K(-1000.0%) | $49.00 K(-3.9%) |
| Mar 2009 | - | -$3000.00(-112.0%) | $51.00 K(-5.6%) |
| Dec 2008 | $54.00 K(-99.9%) | $25.00 K(>+9900.0%) | $54.00 K(+10.2%) |
| Sept 2008 | - | $0.00(-100.0%) | $49.00 K(-116.2%) |
| June 2008 | - | $29.00 K(>+9900.0%) | -$303.00 K(-100.8%) |
| Mar 2008 | - | $0.00(-100.0%) | $37.26 M(0.0%) |
| Dec 2007 | $37.26 M | $20.00 K(-105.7%) | $37.26 M(-0.0%) |
| Sept 2007 | - | -$352.00 K(-100.9%) | $37.27 M(-1.0%) |
| June 2007 | - | $37.59 M(>+9900.0%) | $37.63 M(>+9900.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2007 | - | $0.00(-100.0%) | $76.00 K(-3.8%) |
| Dec 2006 | $79.00 K(-33.6%) | $34.00 K(+385.7%) | $79.00 K(-10.2%) |
| Sept 2006 | - | $7000.00(-80.0%) | $88.00 K(+7.3%) |
| June 2006 | - | $35.00 K(+1066.7%) | $82.00 K(-25.5%) |
| Mar 2006 | - | $3000.00(-93.0%) | $110.00 K(-7.6%) |
| Dec 2005 | $119.00 K(-99.0%) | $43.00 K(+4200.0%) | $119.00 K(-11.9%) |
| Sept 2005 | - | $1000.00(-98.4%) | $135.00 K(-0.7%) |
| June 2005 | - | $63.00 K(+425.0%) | $136.00 K(-98.9%) |
| Mar 2005 | - | $12.00 K(-79.7%) | $11.94 M(-0.6%) |
| Dec 2004 | $12.01 M(>+9900.0%) | $59.00 K(+2850.0%) | $12.01 M(+0.0%) |
| Sept 2004 | - | $2000.00(-100.0%) | $12.01 M(+0.0%) |
| June 2004 | - | $11.87 M(>+9900.0%) | $12.01 M(+7005.9%) |
| Mar 2004 | - | $86.00 K(+48.3%) | $169.00 K(+103.6%) |
| Dec 2003 | $83.00 K(+10.7%) | $58.00 K(>+9900.0%) | $83.00 K(+72.9%) |
| Sept 2003 | - | $0.00(-100.0%) | $48.00 K(0.0%) |
| June 2003 | - | $25.00 K(>+9900.0%) | $48.00 K(-36.0%) |
| Mar 2003 | - | $0.00(-100.0%) | $75.00 K(0.0%) |
| Dec 2002 | $75.00 K(+13.6%) | $23.00 K(>+9900.0%) | $75.00 K(-108.0%) |
| Sept 2002 | - | $0.00(-100.0%) | -$933.60 K(-1144.3%) |
| June 2002 | - | $52.00 K(>+9900.0%) | $89.40 K(+35.5%) |
| Mar 2002 | - | $0.00(-100.0%) | $66.00 K(0.0%) |
| Dec 2001 | $66.00 K(-102.2%) | -$985.60 K(-196.3%) | $66.00 K(-100.3%) |
| Sept 2001 | - | $1.02 M(+3476.9%) | -$23.91 M(+752.5%) |
| June 2001 | - | $28.60 K(>+9900.0%) | -$2.80 M(-5.8%) |
| Mar 2001 | - | $0.00(-100.0%) | -$2.98 M(-3.0%) |
| Dec 2000 | -$3.07 M(-611.3%) | -$24.96 M(-212.8%) | -$3.07 M(-114.1%) |
| Sept 2000 | - | $22.13 M(<-9900.0%) | $21.72 M(-3056.9%) |
| June 2000 | - | -$143.20 K(+56.7%) | -$734.60 K(-17.6%) |
| Mar 2000 | - | -$91.40 K(-47.5%) | -$891.40 K(-248.6%) |
| Dec 1999 | $600.00 K(-300.0%) | -$174.10 K(-46.6%) | $600.00 K(-240.9%) |
| Sept 1999 | - | -$325.90 K(+8.6%) | -$425.90 K(+325.9%) |
| June 1999 | - | -$300.00 K(-121.4%) | -$100.00 K(<-9900.0%) |
| Mar 1999 | - | $1.40 M(-216.7%) | $0.00(-100.0%) |
| Dec 1998 | -$300.00 K(-107.0%) | -$1.20 M(<-9900.0%) | -$300.00 K(-114.3%) |
| Sept 1998 | - | $0.00(-100.0%) | $2.10 M(-43.2%) |
| June 1998 | - | -$200.00 K(-118.2%) | $3.70 M(-31.5%) |
| Mar 1998 | - | $1.10 M(-8.3%) | $5.40 M(+25.6%) |
| Dec 1997 | $4.30 M(-39.4%) | $1.20 M(-25.0%) | $4.30 M(+138.9%) |
| Sept 1997 | - | $1.60 M(+6.7%) | $1.80 M(+63.6%) |
| June 1997 | - | $1.50 M(>+9900.0%) | $1.10 M(-62.1%) |
| Mar 1997 | - | $0.00(-100.0%) | $2.90 M(-59.2%) |
| Dec 1996 | $7.10 M(-26.0%) | -$1.30 M(-244.4%) | $7.10 M(-25.3%) |
| Sept 1996 | - | $900.00 K(-72.7%) | $9.50 M(-38.3%) |
| June 1996 | - | $3.30 M(-21.4%) | $15.40 M(+26.2%) |
| Mar 1996 | - | $4.20 M(+281.8%) | $12.20 M(+27.1%) |
| Dec 1995 | $9.60 M(-8.6%) | $1.10 M(-83.8%) | $9.60 M(+2.1%) |
| Sept 1995 | - | $6.80 M(+6700.0%) | $9.40 M(+129.3%) |
| June 1995 | - | $100.00 K(-93.8%) | $4.10 M(-60.2%) |
| Mar 1995 | - | $1.60 M(+77.8%) | $10.30 M(-1.9%) |
| Dec 1994 | $10.50 M(<-9900.0%) | $900.00 K(-40.0%) | $10.50 M(+11.7%) |
| Sept 1994 | - | $1.50 M(-76.2%) | $9.40 M(+17.5%) |
| June 1994 | - | $6.30 M(+250.0%) | $8.00 M(+370.6%) |
| Mar 1994 | - | $1.80 M(-1000.0%) | $1.70 M(-1800.0%) |
| Dec 1993 | -$100.00 K(-100.5%) | -$200.00 K(-300.0%) | -$100.00 K(-125.0%) |
| Sept 1993 | - | $100.00 K(>+9900.0%) | $400.00 K(-91.1%) |
| June 1993 | - | $0.00(0.0%) | $4.50 M(-47.1%) |
| Mar 1993 | - | $0.00(-100.0%) | $8.50 M(-56.4%) |
| Dec 1992 | $19.50 M(+828.6%) | $300.00 K(-92.9%) | $19.50 M(-6.3%) |
| Sept 1992 | - | $4.20 M(+5.0%) | $20.80 M(+23.1%) |
| June 1992 | - | $4.00 M(-63.6%) | $16.90 M(+29.0%) |
| Mar 1992 | - | $11.00 M(+587.5%) | $13.10 M(+523.8%) |
| Dec 1991 | $2.10 M(-4.5%) | $1.60 M(+433.3%) | $2.10 M(+5.0%) |
| Sept 1991 | - | $300.00 K(+50.0%) | $2.00 M(+17.6%) |
| June 1991 | - | $200.00 K(>+9900.0%) | $1.70 M(-19.0%) |
| Mar 1991 | - | $0.00(-100.0%) | $2.10 M(-4.5%) |
| Dec 1990 | $2.20 M(+214.3%) | $1.50 M(>+9900.0%) | $2.20 M(+214.3%) |
| Sept 1990 | - | $0.00(-100.0%) | $700.00 K(0.0%) |
| June 1990 | - | $600.00 K(+500.0%) | $700.00 K(+600.0%) |
| Mar 1990 | - | $100.00 K | $100.00 K |
| Dec 1989 | $700.00 K | - | - |
FAQ
- What is Heron Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Heron Therapeutics?
- What is Heron Therapeutics annual CFF year-on-year change?
- What is Heron Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Heron Therapeutics?
- What is Heron Therapeutics quarterly CFF year-on-year change?
- What is Heron Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Heron Therapeutics?
- What is Heron Therapeutics TTM CFF year-on-year change?
What is Heron Therapeutics annual cash flow from financing activities?
The current annual CFF of HRTX is $54.11 M
What is the all time high annual CFF for Heron Therapeutics?
Heron Therapeutics all-time high annual cash flow from financing activities is $357.61 M
What is Heron Therapeutics annual CFF year-on-year change?
Over the past year, HRTX annual cash flow from financing activities has changed by -$20.95 M (-27.91%)
What is Heron Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of HRTX is $14.00 K
What is the all time high quarterly CFF for Heron Therapeutics?
Heron Therapeutics all-time high quarterly cash flow from financing activities is $370.42 M
What is Heron Therapeutics quarterly CFF year-on-year change?
Over the past year, HRTX quarterly cash flow from financing activities has changed by -$53.78 M (-99.97%)
What is Heron Therapeutics TTM cash flow from financing activities?
The current TTM CFF of HRTX is $716.00 K
What is the all time high TTM CFF for Heron Therapeutics?
Heron Therapeutics all-time high TTM cash flow from financing activities is $526.17 M
What is Heron Therapeutics TTM CFF year-on-year change?
Over the past year, HRTX TTM cash flow from financing activities has changed by -$53.63 M (-98.68%)